Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
